M I C R 0 A N G lOP A T HIe haemolytic anaemia (M.A.H.A.) is the name given by Brain et al. (1962) to describe the anaemia often accompanied by thrombocytopenia which occurs in a number of diseases and clinical situations. One of these is thrombotic thrombocytopenic purpura (thrombotic microangiopathy), a case of which is reviewed on page 190of this issue of the Scottish Medical Journal by Drs Thomson and Gardner. The principal haematological features seen are anaemia, thrombocytopenia, reticulocytosis and sometimes normoblastaemia. Fragmented and irregularly contracted erythrocytes termed schistocytes and helmet cells are seen in the blood film and are of diagnostic importance. A positive antiglobulin test, however, is rare (Dacie, 1967) . Associated clinical features include pallor, sometimes slight icterus and oliguria or anuria. Bruising and petechiae are often present, and there may be bleeding from mucous membranes. M.A.H.A. also occurs in the haemolyticuraemic syndrome of infancy and childhood, malignant hypertension, pre-eclampsia and eclampsia, renal cortical necrosis, acute necrotizing glomerulonephritis, polyarteritis and disseminated carcinoma. The pathogenesis of many of the cases seen is unknown and has been attributed on various occasions to immunulogical factors (Lancet, 1968), bacterial endotoxin (Shwartzman et al., 1936) , virus infection (Giantonio et al., 1964) and hypersensitivity (McQuiggan et al., 1965) . It should be clearly understood that the terms M.A.H.A. and haemolytic-uraemic syndrome are not diagnoses in themselves but haematological and clinical manifestations of some primary disease. Dacie (1967) has reviewed the haemolysis associated with acute renal failure and has proposed the following classification: 1. An acute illness affecting infants or young children often called the haemolytic-uraemic syndrome; 2. An illness mainly affecting adults, with an acute onset and with more diverse clinical features, generally referred to as thrombotic thrombocytopenic purpura (T.T.P.); 3. As a terminal feature in some cases of acutely progressive malignant hypertension or as an important manifestation of eclampsia, pre-eclampsia or renal failure and hypertension occurring after childbirth.
Renal lesions found at necropsy or on biopsy, from patients with features of M.A.H.A., vary from focal glomerulonephritis, thrombotic microangiopathy or necrotising arteriolitis to bilateral renal cortical necrosis. Thrombi may be found in the glomerular tufts and fibrinoid necrosis and intraluminar thrombi are seen in the afferent arterioles. In children the vascular changes are usually confined to the kidney but in adults many organs may be involved, particularly the brain. The latter lesions are probably responsible for the well recognised bizarre neurological clinical manifestations seen in T.T.P.
The mechanisms involved in the production of haemolysis and thrombocytopenia have been the subject of much speculation in recent years. It is postulated that disseminated intravascular coagulation (D.I.e.) plays an important role in the following way. Intravascular conversion of fibrinogen to fibrin leads to the formation of normal polymerized fibrin in small blood vessels. This is lysed by plasmin which has been formed from circulating plasminogen, releasing fibrin degradation products (F.D.P.'s.). During the whole process various coagulation factors are consumed notably fibrinogen, platelets, factor V and factor VIII. In the presence of thrombocytopenia and circulating F.D.P.'s further fibrin formation is abnormal resulting in the appearance of loose, course, pourous strands of fibrin instead of a condensed, impenetrable clot. Mechanical arrest and trauma to the erythrocytes by these strands is believed to be responsible for the haemolysis Leading Article and for the fragmentation of the red cells so characteristically seen in the blood film. In 1962, Brain et al., suggested that red cell fragmentation in M.A.H.A. was brought about by the passage of these cells through abnormal vessels. Bull et al. (1968) showed in vitro that red cells arrested on a fibrin strand while moving through a loose fibrin clot with the velocity of arterial blood flow were bent over the strands by the force of the blood flow and eventually fragmented. Systems in which erythrocytes perfused artificial 'clots' made of glass fibre and nylon also caused these cells to fragment. The workers deduced from these findings that this process seemed to depend on rapid blood flow together with arrest of individual erythrocytes by any obstruction of small dimensions. Rubenberg et al. (1968) , produced D.LC. in rabbits with Arvin (the purified coagulation fraction of Malayan Pit Viper venom) and also inhibited the animals' fibrinolytic system, thus maintaining pourous fibrin thrombi in the vessels. Haemoglobinaemia and red cell fragmentation appeared in the circulation. It was suggested that this interaction occurred in human disease and was the causal mechanism of M.A.H.A.
Intravascular coagulation seems to play an important role (Piel & Phibbs, 1966; Lanzkowsky & McCrory 1967; and certain similarities to the Shwartzman reaction in animals has been noted. Brain and Hourihane (1967) produced the generalized Shwartzman reaction in rabbits by two spaced injections of endotoxin, which produced wide spread occlusion of small vessels. They showed a fall in packed cell volume and a rise in plasma haemoglobin which did not seem to be due to the direct action of endotoxin on the red cells. The most marked rise in plasma haemoglobin occurred during the first few hours after the second endotoxin injection when intravascular coagulation and fibrin deposition was taking place. Administration of heparin prevented both the Shwartzman reaction and the rise in plasma haemoglobin, In infants with the haemolytic-uraemic syndrome low levels of coagulation factors have been reported (Desmit et al., 1965; Monnens & Schretlen, 1967) , but in classical T.T.P. few 188 coagulation studies have been carried out. found normal fibrinogen levels in 6 patients with M.A.H.A., 5 of whom showed a marked increase of fibrinogen catabolism as measured by 131 1 labelled fibrinogen. It would appear that this measurement is the most sensitive method of detecting intravascular coagulation in such patients. Thrombocytopenia may be explained both by the removal of platelets at the site of vascular damage, through direct adherence to fibrin or collagen, and by the release of ADP and thromboplastins from red eels undergoing fragmentation, leading to platelet aggregation and deposition.
The treatment of M.A.H.A., whatever the cause of the syndrome, has improved considerably with the use of heparin. Peritoneal dialysis or haemo-dialysis for renal failure plus vigorous control of hypertension are, of course, mandatory and anaemia usually requires blood transfusion. In the past the most popular specific therapy has been ACTH or corticosteroids, but results with these drugs have generally been disappointing. Piel and Phibbs (1966) did demonstrate a favourable response in some cases but Amorosi and Ultmann (1966) reviewing 255 patients considered prognosis to be uninfluenced by steroid therapy. Blix and Jacobsen (1966) went so far as to point out the possible accelerating effect of prednisone on the course of the disease in some cases. Splenectomy has not been a popular form of treatment and results have been generally disappointing; nevertheless, Cahalane and Horn (1959) , reviewing 18 patients who underwent splenectomy, reported 5 remissions following this operation.
Heparin therapy now seems to be the treatment of choice. Experimentally the effect of heparin in neutralising the effects of the Shwartzman reaction have been well demonstrated (Good & Thomas, 1953; Brain & Hourihane, 1967) . Its use in L'I'P, was first suggested by Singer et al. in 1947. The most recent report on the use of this drug in M.A.H.A. describes the response of 3 children and 4 adult women. One child and 3 adults treated within 10 days of the onset of the illness recovered rapidly~nd completely from their anaemia, thrombocytopenia and uraemia. The authors advocate an early trial of heparin in all patients with severe M.A.H.A. irrespective of the presumed causation. They do stress that when the course of the vascular disease is persistent, as might be the case in some patients with T.T.P., heparin treatment could be of only transient benefit. In these cases corticosteroids should also be considered in the treatment of the primary vascular disease.
Since Moschowitz first described T.T.P. in 1924, our understanding of mechanisms in M.A.H.A. have advanced considerably but there are still large gaps in our knowledge of the syndrome. Much work remains to be done especially with regard to the production of thrombocytopenia and the fate of the platelets. There is little doubt about the part D.I.C. has to play in the production of haemolysis, red cell fragmentation and thrombocytopenia. Heparin should be given an early trial even in the presence of bleeding and bruising (a statement which many physicians still find difficult to accept). The progress of the patient can be gauged by his clinical state, frequent platelet counts, and plasma haemoglobin estimations. Obviously the underlying cause of each case will govern the prognosis, but a certain amount of cautious optimism is certainly justified.
